Ciforadenant clinical trials
Also written V81444 and CPI-444.
- studies test it
- 9
- open now
- 0
- in phase 3
- 0
- first study started
- 2011
How each study uses ciforadenant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
9 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 1
Corvus Pharmaceuticals, Inc. (4) · Vernalis (R&D) Ltd (3) · M.D. Anderson Cancer Center (1) · Hoffmann-La Roche (1)
Often tested with
Tested in the same studies.
CPI-006 (1) · Cobimetinib (1) · Cibisatamab (1) · Docetaxel (1) · Pemetrexed (1) · Carboplatin (1) · Gemcitabine (1) · Linagliptin (1)
Studies
Open first, then newest update. How each study uses ciforadenant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 9
- Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.Active, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT05501054Written as Ciforadenant
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03337698Written as CPI-444
- CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced CancersCompletedPhase 1Corvus Pharmaceuticals, Inc.NCT03454451Written as CPI-006 + ciforadenant
- Study of Ciforadenant in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple MyelomaCompletedPhase 1Corvus Pharmaceuticals, Inc.NCT04280328Written as Ciforadenant
- Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced CancersCompletedPhase 1Corvus Pharmaceuticals, Inc.NCT02655822Written as Ciforadenant
- Study to Evaluate the Pharmacokinetics of a New Tablet Formulation of CPI-444 in Fed and Fasted Healthy Male and Female SubjectsCompletedPhase 1Corvus Pharmaceuticals, Inc.NCT03237988Written as CPI-444 Capsules
- Safety, Tolerability, PK & Efficacy of V81444 in Volunteers With Attention Deficit/ Hyperactivity Disorder (ADHD)CompletedPhase 1/2Vernalis (R&D) LtdNCT02253745Written as V81444
- A Study in Healthy Male Volunteers to Investigate a New Drug for the Treatment of Parkinson's DiseaseCompletedPhase 1Vernalis (R&D) LtdNCT02764892Written as V81444
- A Clinical Trial to Find Out V81444's Side Effects and Blood Levels in Healthy MenCompletedPhase 1Vernalis (R&D) LtdNCT01634568Written as V81444
Codes
What other systems call ciforadenant · ClinicalTrials.gg INT001147
- MeSH (NLM) C000633770ciforadenantOne source NLM
- UNII (FDA) 8KFO2187CPCIFORADENANTConfirmed FDA, NLM
- NCI Thesaurus C125659CiforadenantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000633770 | ciforadenant | One source NLM |
| UNII (FDA) | 8KFO2187CP | CIFORADENANT | Confirmed FDA, NLM |
| NCI Thesaurus | C125659 | Ciforadenant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.